Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2582
http://purl.obolibrary.org/obo/NCIT_C2582
|
|---|---|
| Preferred Name | Yttrium Y-90 Epratuzumab Tetraxetan |
| Definitions |
A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation. |
|---|---|
| prefLabel | Yttrium Y-90 Epratuzumab Tetraxetan
|
| label | Yttrium Y-90 Epratuzumab Tetraxetan
|
| PDQ_Closed_Trial_Search_ID | 43648
|
| code | C2582
|
| Has_Target | |
| prefixIRI | NCIT:C2582
|
| in_subset |
See more
See less
|
| Display_Name | Yttrium Y-90 Epratuzumab Tetraxetan
|
| Preferred_Name | Yttrium Y-90 Epratuzumab Tetraxetan
|
| FDA_UNII_Code | J36232195E
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C16H25N5O7.Y
|
| Maps_To | Yttrium Y-90 Epratuzumab Tetraxetan
|
| CAS_Registry | 501423-25-2
|
| NCI_Drug_Dictionary_ID | 43648
|
| Legacy Concept Name | Y_90_Humanized_Monoclonal_Antibody_LL2
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 43648
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C0879352
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |